CAPR Capricor Therapeutics
- 5.470
- +0.230+4.39%
- 5.440
- -0.030-0.55%
Capricor Therapeutics News
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
Capricor Therapeutics Analyst Ratings
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Capricor Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), CVRx (CVRX) and Capricor Therapeutics (CAPR)
Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics With Overweight Rating, Announces Price Target of $8
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics: Solid Financials and Promising DMD Trial Progression Support Buy Rating
Capricor Therapeutics Exceeds Expectations: Promising Financial Results and Operational Developments Lead to Buy Rating
Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)
HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $40
Capricor Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Advanced Human Imaging (AHI) and Capricor Therapeutics (CAPR)
Capricor Therapeutics Analyst Ratings
H.C. Wainwright Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)
Maxim Group Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
Analysis
Price Target
No Data
